AVEO Oncology Inc (AVEO) - Financial and Strategic SWOT Analysis Review

June 2019 | 52 pages | ID: A3E4CC49DC6EN
GlobalData

Abstracts

AVEO Oncology Inc (AVEO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

AVEO Oncology Inc (AVEO) is a biopharmaceutical company which focuses on the discovery, development and commercialization of drugs for the treatment of various types of cancers. Its proprietary platform delivers insights into cancer and related diseases. AVEO develops its lead candidate Tivozanib in North America as a treatment for renal cell carcinoma, Ficlatuzumab AV-203, AV-380 and AV-353. The company has strategic partnerships and collaborations with key biopharmaceutical companies. AVEO is headquartered in Cambridge, Massachusetts, the US.

AVEO Oncology Inc Key Recent Developments

May 09,2019: AVEO reports first quarter 2019 financial results and provides business update
Mar 14,2019: AVEO reports full year 2018 financial results and provides business update
Feb 26,2019: AVEO Oncology names Gregory T. Mayes board of director
Feb 25,2019: Pomerantz law firm announces the filing of a class action against Aveo Pharmaceuticals and certain officers
Nov 09,2018: AVEO reports third quarter 2018 financial results and provides business update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

AVEO Oncology Inc - Key Facts
AVEO Oncology Inc - Key Employees
AVEO Oncology Inc - Key Employee Biographies
AVEO Oncology Inc - Major Products and Services
AVEO Oncology Inc - History
AVEO Oncology Inc - Company Statement
AVEO Oncology Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
AVEO Oncology Inc - Business Description
AVEO Oncology Inc - Corporate Strategy
AVEO Oncology Inc - SWOT Analysis
SWOT Analysis - Overview
AVEO Oncology Inc - Strengths
AVEO Oncology Inc - Weaknesses
AVEO Oncology Inc - Opportunities
AVEO Oncology Inc - Threats
AVEO Oncology Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

AVEO Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
AVEO Oncology Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
AVEO Oncology Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 09, 2019: AVEO reports first quarter 2019 financial results and provides business update
Mar 14, 2019: AVEO reports full year 2018 financial results and provides business update
Feb 26, 2019: AVEO Oncology names Gregory T. Mayes board of director
Feb 25, 2019: Pomerantz law firm announces the filing of a class action against Aveo Pharmaceuticals and certain officers
Nov 09, 2018: AVEO reports third quarter 2018 financial results and provides business update
Aug 07, 2018: Aveo reports second quarter 2018 financial results and provides business update
Jun 15, 2018: AVEO Oncology added to the Russell 2000, Russell 3000, and Russell Microcap indexes
May 08, 2018: AVEO Reports First Quarter 2018 Financial Results and Provides Business Update
Mar 13, 2018: AVEO Reports Full Year 2017 Financial Results and Provides Business Update

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

AVEO Oncology Inc, Key Facts
AVEO Oncology Inc, Key Employees
AVEO Oncology Inc, Key Employee Biographies
AVEO Oncology Inc, Major Products and Services
AVEO Oncology Inc, History
AVEO Oncology Inc, Subsidiaries
AVEO Oncology Inc, Key Competitors
AVEO Oncology Inc, Ratios based on current share price
AVEO Oncology Inc, Annual Ratios
AVEO Oncology Inc, Annual Ratios (Cont...1)
AVEO Oncology Inc, Interim Ratios
AVEO Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
AVEO Oncology Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
AVEO Oncology Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

AVEO Oncology Inc, Performance Chart (2014 - 2018)
AVEO Oncology Inc, Ratio Charts
AVEO Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
AVEO Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

COMPANIES MENTIONED

Roche Laboratories Inc
Onyx Pharmaceuticals Inc
Novartis Pharmaceuticals Corp
Mirati Therapeutics Inc
Merrimack Pharmaceuticals Inc
Galaxy Biotech LLC
Daiichi Sankyo Inc